文献速递泌尿男性生殖肿瘤

卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌的II期试验及基因组相关性

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
PubMed 文献 · J Clin Oncol · 2022-03-17

这项II期试验评估卡博替尼联合纳武利尤单抗治疗晚期非透明细胞肾细胞癌的疗效与安全性。队列1(乳头状、未分类或易位相关RCC,n=40)客观缓解率为47.5%(95%CI 31.5-63.9),中位无进展生存期12.5个月;队列2(嫌色细胞RCC,n=7)未见缓解。整体3/4级治疗相关不良事件发生率为32%。

要点

  • 队列1客观缓解率47.5%(95%CI 31.5-63.9),中位无进展生存期12.5个月。
  • 队列2(嫌色细胞RCC,n=7)无客观缓解,1例疾病稳定超过1年。
  • 3/4级治疗相关不良事件发生率32%,13%和17%患者分别因毒性停用卡博替尼和纳武利尤单抗。

核心结论

  • 卡博替尼联合纳武利尤单抗在本试验所测试的大多数非透明细胞RCC变异型中显示出有前景的疗效,尤其是具有显著乳头状特征者,而嫌色细胞RCC的治疗效果有限。
  • 非透明细胞RCC变异型中的基因组发现作为缓解预测因子值得进一步研究。

研究设计与样本

  • II期试验,纳入既往接受0-1线系统治疗(排除既往免疫检查点抑制剂)的晚期非透明细胞肾细胞癌患者。
  • 患者接受卡博替尼40 mg每日一次联合纳武利尤单抗240 mg每2周一次或480 mg每4周一次。
  • 队列1纳入乳头状、未分类或易位相关RCC患者;队列2纳入嫌色细胞RCC患者。
  • 主要终点为RECIST 1.1评估的客观缓解率;次要终点包括无进展生存期、总生存期和安全性;下一代测序结果与缓解进行相关性分析。

主要发现

  • 共47例患者接受治疗,中位随访13.1个月。
  • 队列1(n=40)客观缓解率为47.5%(95%CI 31.5-63.9),中位无进展生存期12.5个月(95%CI 6.3-16.4),中位总生存期28个月(95%CI 16.3-不可评估)。
  • 队列2(n=7)未观察到缓解;1例患者疾病稳定超过1年。
  • 3/4级治疗相关不良事件见于32%的治疗患者;因毒性停用卡博替尼和纳武利尤单抗的患者分别为13%和17%。
  • 队列1常见突变为NF2和FH,队列2常见突变为TP53和PTEN;携带NF2或FH突变的12例患者中10例观察到客观缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non-clear-cell renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients had advanced non-clear-cell renal carcinoma who underwent 0-1 prior systemic therapies excluding prior immune checkpoint inhibitors. Patients received cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks or 480 mg once every 4 weeks. Cohort 1 enrolled patients with papillary, unclassified, or translocation-associated RCC; cohort 2 enrolled patients with chromophobe RCC. The primary end point was objective response rate (ORR) by RECIST 1.1; secondary end points included progression-free survival, overall survival, and safety. Next-generation sequencing results were correlated with response. RESULTS: A total of 47 patients were treated with a median follow-up of 13.1 months. Objective response rate for cohort 1 (n = 40) was 47.5% (95% CI, 31.5 to 63.9), with median progression-free survival of 12.5 months (95% CI, 6.3 to 16.4) and median overall survival of 28 months (95% CI, 16.3 to not evaluable). In cohort 2 (n = 7), no responses were observed; one patient had stable disease > 1 year. Grade 3/4 treatment-related adverse events were observed in 32% treated patients. Cabozantinib and nivolumab were discontinued because of toxicity in 13% and 17% of patients, respectively. Common mutations included NF2 and FH in cohort 1 and TP53 and PTEN in cohort 2. Objective responses were seen in 10/12 patients with either NF2 or FH mutations. CONCLUSION: Cabozantinib plus nivolumab showed promising efficacy in most non-clear-cell RCC variants tested in this trial, particularly those with prominent papillary features, whereas treatment effects were limited in chromophobe RCC. Genomic findings in non-clear-cell RCC variants warrant further study as predictors of response.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lee CH, Voss MH, Carlo MI, et al. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022. PMID: 35298296. doi:10.1200/JCO.21.01944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。